| Health / Medical Topics |
Proteasome Inhibitor MLN9708
An orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Proteasome inhibitor MLN9708 inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated. (NCI Thesaurus)
YOU MAY ALSO LIKE
A drug that blocks the action of proteasomes. A proteasome is a large protein complex that helps destroy other cellular proteins when…
Proteasome Inhibition involves interference with, or restraint of, the activities of macromolecular multicatalytic cellular structures in the cytosol and nucleus with multiple…
Proteasome Binding involves temporary non-covalent interaction through intermolecular physical forces of attraction with multicatalytic macromolecular cellular structures in the cytosol and nucleus…
Proteasome assembly chaperone 2 (264 aa, ~29 kDa) is encoded by the human PSMG2 gene. This protein plays a role in promoting…
Proteasome activator complex subunit 3 (254 aa, ~30 kDa) is encoded by the human PSME3 gene. This protein is involved in the…
26S proteasome non-ATPase regulatory subunit 10 (226 aa, ~24 kDa) is encoded by the human PSMD10 gene. This protein is involved in…
